In:
Journal of Pediatric Gastroenterology and Nutrition, Wiley
Kurzfassung:
We demonstrated the efficacy of IFX as second line therapy after loss of response (LOR) or intolerance to ADA in pediatric CD patients at 1 year. IFX could be an interesting therapeutic choice in patients experiencing LOR to ADA before switching for another class of biotherapy. What is Known? Adalimumab (ADA) and Infliximab (IFX) are recommended for induction and maintenance of remission in pediatric Crohn's disease (CD). Currently ADA is often used as first line therapy.
Materialart:
Online-Ressource
ISSN:
0277-2116
,
1536-4801
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2024
ZDB Id:
2078835-6